Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02837042|
Recruitment Status : Terminated (Poor accrual)
First Posted : July 19, 2016
Results First Posted : June 21, 2022
Last Update Posted : June 21, 2022
|Condition or disease||Intervention/treatment||Phase|
|Penile Squamous Cell Carcinoma||Drug: Pembrolizumab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Following Previous Chemotherapy|
|Study Start Date :||October 2016|
|Actual Primary Completion Date :||October 2019|
|Actual Study Completion Date :||October 2019|
Experimental: Pembrolizumab 200 mg
Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.
Pembrolizumab will be administered intravenously every 3 weeks.
Other Name: Keytruda
- Objective Tumor Response Rate [ Time Frame: Baseline up to two years ]The response rate will be evaluated every 3 weeks using the criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in addition to immune related criteria based on patterns of response.
- Progression-free Survival (PFS) [ Time Frame: Baseline up to two years ]The duration of time from the start of treatment to the first documentation of tumor progression.
- Overall Survival [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months ]Length of subject survival after starting study treatment
- Number of Patients With Adverse Events [ Time Frame: Baseline up to two years ]Adverse events reporting will be graded following the National Cancer Institute of Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02837042
|United States, Alabama|
|University of Alabama at Birmingham|
|Birmingham, Alabama, United States, 35294|
|United States, California|
|University of Southern California|
|Los Angeles, California, United States, 90033|
|United States, Georgia|
|Winship Cancer Institute at Emory University|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Lisle Nabell, MD||University of Alabama at Birmingham|